logo-loader
ASX:PAR

Paradigm Biopharmaceuticals Ltd

Recieve alerts
Market:
ASX
Market Cap:
$276.78 m
Price
0.00
Change
0.05%
52 weeks high
2.15
52 weeks low
0.69
;

Viewing results 1-25 of 74

Paradigm Biopharmaceuticals files Investigational New Drug submission for ZilosulÒ with FDA

ZilosulÒ (iPPS) is a potential first-line therapeutic treatment for osteoarthritis and other diseases affecting the musculoskeletal system....

1 week, 5 days ago

Paradigm Biopharmaceuticals director acquires 140,000 shares valued at almost $170,000

Non-executive director Chris Fullerton participated in a $26.3 million entitlement offer and has also purchased shares on-market....

on 3/7/19

Paradigm Biopharmaceuticals CEO shows faith in company with $49,000 on-market purchase

To facilitate its ongoing development and growth, the company signed employment agreements with five new staff members in late June. ...

on 2/7/19

Paradigm Biopharmaceuticals Ltd fully funded as it advances iPPS development

The company is focused on creating commercial opportunities that will generate potential revenue from early sales of finished product or through partnering/commercial transactions....

on 28/6/19

Paradigm Biopharmaceuticals receives positive results for Ross River clinical trial

The trial was treating patients with joint pain or joint stiffness....

on 4/6/19

Paradigm Biopharmaceuticals receives more positive real-world patient data

Doctors can administer the treatment to patients under the TGA Special Access Scheme....

on 28/5/19

Paradigm Biopharmaceuticals completes retail component of $26.3 million entitlement offer

The retail entitlement offer had a take-up rate of about 54.7% for acceptances of entitlements and applications for additional shares by eligible retail shareholders. ...

on 9/5/19

Paradigm Biopharmaceuticals completes institutional component of $26.3 million entitlement offer

Along with the entitlement offer, Paradigm has raised $51.6 million via a placement to professional, institutional and sophisticated investors....

on 24/4/19

Paradigm Biopharmaceuticals director buys shares on-market

The company has today commenced the retail component of its $77.9 million capital raising....

on 23/4/19

Paradigm Biopharmaceuticals secures $61.3 million in first stage of raising

The capital raising has attracted a number of international institutional investors....

on 17/4/19

Paradigm Biopharmaceuticals phase 2b trial achieves key endpoints in OA of the knee

OA remains the most common form of joint disease globally, affecting over 30 million adults in the US alone....

on 15/4/19

Paradigm Biopharmaceuticals raising $77.9 million to fund its pivotal phase 3 OA trial

In conjunction with the capital raise, Paradigm has revealed that it has successfully met the primary and secondary endpoints of its phase 2b trial in OA of the knee....

on 15/4/19

Paradigm Biopharmaceuticals gets a speeding ticket for 18% price increase

Over the past year, shares have come from 29 cents to be trading at around $1.90....

on 27/3/19

Paradigm Biopharmaceuticals director shows confidence with on-market share purchase

The company has begun discussions with International key opinion leaders for mucopolysaccharidoses (MPS) clinical trial design and site selection....

on 8/3/19

Paradigm Biopharmaceuticals moving towards phase 2/3 MPS clinical trial

MPS or mucopolysaccharidoses is an orphan indication with market exclusivity and high profit margins....

on 14/2/19

Paradigm Biopharmaceuticals to court partners and licensees for OA drug commercialisation

The injectable PPS trial has had a clinically meaningful and statistically significant result in patients with arthritic knee pain....

on 23/1/19

Paradigm Biopharmaceutical shares surge on clinical trial success

The trial met the primary endpoint with a change in the knee injury and OA outcome score, confirming the potential for safe and effective treatment with iPPS. ...

on 18/12/18

Paradigm Biopharmaceuticals to talk clinical trial results on conference call tomorrow morning

The call will discuss the phase IIb randomised double-blind placebo controlled multicentre study....

on 17/12/18

Paradigm Biopharmaceuticals has results pending for phase 2b clinical trial

A trading halt will remain in place until the start of trading on Tuesday, December 18, or when an announcement is released....

on 14/12/18

Paradigm Biopharmaceuticals chief executive Paul Rennie buys more shares

Paradigm is focused on repurposing the drug pentosan polysulfate sodium in its injectable form ...

on 13/12/18

Paradigm Biopharmaceuticals gets more real world evidence of treatment success

Patients access the treatment through their doctor under the TGA’s Special Access Scheme....

on 6/12/18

Paradigm Biopharmaceuticals ‘next Australian blockbuster biotech’, according to Fiftyone Capital

Paradigm is focused on repurposing the drug pentosan polysulfate sodium in its injectable form (iPPS) for orthopaedic treatment of OA and bone marrow edema lesions (BMEL)....

on 3/12/18

Paradigm Biopharmaceuticals’ positive trial results potentially transformational, says Morgans research

The readout of clinical trial results is expected in December....

on 30/11/18

Paradigm Biopharmaceuticals signs agreement for use of iPPS in treatment of MPS

An exclusive licence agreement has been executed with the Icahn School of Medicine at Mount Sinai, New York....

on 22/11/18